natgillin/translations-raw huggingface dataset:
• You should also tell your doctor immediately if you develop a medical condition (known as Thrombotic Thrombocytopenic Purpura) that includes altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas) (see section 4 ‘Possible Side Effects') 
• Također, odmah obavijestite svog liječnika ako se pojavi medicinsko stanje (koje se naziva trombotična trombocitopenična purpura) sa simptomima koji uključuju promijenjeno ponašanje, glavobolje, komu, poremećaje vida, epileptičke napadaje, zatajenje bubrega, vrućicu, iscrpljenost, slabost ili krvarenje u želucu, crijevima ili koži (uključujući male crvene točkice ili područja većih modrica) (vidjeti dio 4. "Moguće nuspojave").
Discard any remaining tablets 100 days after first opening of the bottle. 
Baciti sve tablete preostale 100 dana nakon prvog otvaranja bočice.
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers. 
U skladu s gore navedenim rezultatima, metaanaliza, koja je uključivala 6 studija sa 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazala je da je izloženost aktivnom metabolitu smanjena za 28% u umjerenih metabolizatora te 72% u slabih metabolizatora, dok je inhibicija agregacije trombocita (5 μM ADP) smanjena, uz razlikame u vrijednosti IAT-e od 5,9%, odnosno 21,4%, u usporedbi s brzim metabolizatorima.
Driving and using machines Clopidogrel Teva Pharma B.V. is unlikely to affect your ability to drive or operate machinery. 
Klopidogrel Teva Pharma B.V. ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
You should also be given acetylsalicylic acid (a substance used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor. 
Liječnik će Vam propisati i acetilsalicilatnu kiselinu (tvar koju sadržavaju mnogi lijekovi za ublažavanje boli i snižavanje povišene temperature, kao i oni za sprječavanje stvaranja krvnih ugrušaka).
Do not store above 25°C. 
Čuvati na temperaturi ispod 25°C.
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co administered with atenolol, nifedipine, or both atenolol and nifedipine. 
Nisu primijećene klinički značajne farmakodinamičke interakcije pri istodobnoj primjeni klopidogrela i atenolola, odnosno nifedipina, ili klopidogrela i ta dva lijeka zajedno.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors, or selective serotonin reuptake inhibitors (SSRIs). 
Kao i u slučaju drugih antitrombocitnih lijekova, klopidogrel s oprezom treba davati bolesnicima koji su izloženi povećanom riziku od krvarenja zbog povreda, kirurških zahvata ili drugih patoloških stanja te bolesnicima koji se liječe s ASK, heparinom, inhibitorima glikoproteina IIb/IIIa ili nesteroidnim protuupalnim lijekovima (NSAIL), uključujući Cox-2 inhibitore ili selektivne inhibitore ponovne pohrane serotonina (SSRI)..
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleeds or blood in the urine. 
Krvarenje se može pojaviti u obliku krvarenja u želucu ili crijevima, modrica, hematoma (neuobičajeno krvarenje ili modrica ispod kože), krvarenja iz nosa ili krvi u mokraći.
Aluminium-aluminium peelable perforated unit-dose blisters, aluminium-aluminium perforated unit dose blisters and HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant. 
Aluminijski blisteri s odvojivom folijom djeljivi na jedinične doze, aluminijski perforirani blisteri djeljivi na jedinične doze i bočice od polietilena visoke gustoće (HDPE) i polipropilenskim zatvaračem ili polipropilenskim sigurnosnim zatvaračem za djecu i silika gelom kao sredstvom za sušenje.
This could indicate that you are suffering from a serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body) 
Ti simptomi mogu upućivati na ozbiljnu bolest koja se zove trombotična trombocitopenična purpura (rijedak poremećaj zgrušavanja krvi koji uzrokuje stvaranje višestrukih krvnih ugrušaka u tijelu)
This leaflet was last revised in: <Month YYYY> Detailed information is available on the European Medicines Agency website: http://www.ema.europa.eu. 
Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu.
Patients should be evaluated for history of hypersensitivity to thienopyridines (such as clopidogrel, ticlopidine, prasugrel) since cross-reactivity among thienopyridines has been reported (see section 4.8). 
Kod bolesnika treba procijeniti prethodnu preosjetljivost na drugi tienopiridin u povijesti bolesti (kao što su klopidogrel tiklopidin, prasugrel) budući da je zabilježena ukrižena reaktivnost među tienopiridinima (vidjeti dio 4.8).
In patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Qwave myocardial infarction): clopidogrel treatment should be initiated with a single 300-mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg na dan).
Nervous system disorders 
Poremećaji živčanog sustava poremećaj okusa
A serious condition called thrombotic thrombocytic purpura (rare disorder of the blood clotting system which causes multiple blood clots to form around the body). 
• ozbiljna bolest koja se zove trombotična trombocitopenična purpura (rijedak poremećaj zgrušavanja krvi koji uzrokuje stvaranje višestrukih krvnih ugrušaka u tijelu).
• You have liver or kidney disease. 
• Ako imate bolest jetre ili bubrega.
• Bruising, haematoma (unusual bleeding under the skin), nose bleeds, bleeding in the stomach or bowels, increased bleeding at the site of a puncture wound 
• modrice, hematomi (neuobičajeno krvarenje ispod površine kože), krvarenje iz nosa, krvarenje u želucu ili crijevima, pojačano krvarenje na mjestu punkcije
• If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Teva Pharma B.V. 
Ako mislite da se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja lijeka Klopidogrel Teva Pharma B.V.
• Heparin (medicine used to prevent blood clotting). 
• heparin (lijek za sprječavanje zgrušavanja krvi),
• Omeprazole, esomeprazole or cimetidine, medicines to treat upset stomach. 
• omeprazol, esomeprazol ili cimetidin, lijekove za ublažavanje želučanih tegoba,
You can take it with or without food. 
Lijek možete uzeti s jelom ili neovisno od jela.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR=-4.0%; CI: -22.5 to 11.7 [p=0.639]). 
U bolesnika koji su u studiju uključeni samo zbog nedavnog infarkta miokarda, klopidogrel je bio brojčano slabiji, ali se statistički nije razlikovao od ASK (RRR = -4,0%; CI: -22,5 do 11,7 [p=0,639]).
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions. 
Međutim, bolesnici koji su sudjelovali u kliničkim ispitivanjima s klopidogrelom istodobno su primali niz lijekova, među kojima su bili diuretici, beta blokatori, ACE inhibitori, antagonisti kalcija, lijekovi za snižavanje kolesterola, koronarni vazodilatatori, antidijabetici (uključujući inzulin), antiepileptici te antagonisti glikoproteina IIb/IIIa i nisu primijećene klinički značajne štetne interakcije.
In a small number of cases, bleeding in the eye, inside the head, the abdomen, the lung and the joints have also been reported. 
U manjem su broju slučajeva zabilježena i krvarenja u oku, glavi, trbušnoj šupljini, plućima ili zglobovima.
14x1 film-coated tablet 28x1 film-coated tablet 30x1 film-coated tablet 50x1 film-coated tablet 84x1 film-coated tablet 90x1 film-coated tablet 100x1 film-coated tablet 
14 x1 filmom obloženih tableta 28 x1 filmom obloženih tableta 30 x1 filmom obloženih tableta 50x1 filmom obloženih tableta 84 x1 filmom obložene tablete 90 x1 filmom obloženih tableta 100 x1 filmom obloženih tableta
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. 
Također, klopidogrel inhibira agregaciju trombocita induciranu drugim agonistima, pored ADP-a, i to tako što blokira pojačanu aktivacijutrombocita oslobođenim ADP-om.
Do not store above 25ºC. 
Čuvati na temperaturi ispod 25ºC.
• Altered behaviour, headaches, coma, visual disturbances, seizures (fitting), kidney failure, fever, extreme tiredness, weakness or bleeding into the stomach, bowels or skin (including small red spots or large bruised areas). 
• promijenjeno ponašanje, glavobolje, komu, poremećaje vida, epileptičke napadaje, zatajenje bubrega, vrućicu, izrazit umor, slabost ili krvarenje u želucu, crijevima ili koži (uključujući manje crvene točkice ili područja većih modrica).
While you are taking Clopidogrel Teva Pharma B.V.: 
Dok uzimate Klopidogrel Teva Pharma B.V.:
Clopidogrel Teva Pharma B.V. is supplied in peelable perforated blisters of aluminium/ aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablet; perforated blisters of aluminium/ aluminium containing 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 tablet or HDPE bottles with polypropylene closures or child resistant polypropylene closures and silica gel desiccant containing 30 or 100 tablets. 
• Klopidogrel Teva Pharma B.V. dostupan je u aluminijskim blisterima s odvojivom folijom djeljivima na jedinične doze koji sadržavaju 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 tableta; aluminijskim perforiranim blisterima djeljivima na jedinične doze koji sadržavaju 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 tableta ili bočicama od polietilena visoke gustoće (HDPE) s polipropilenskim zatvaračem ili polipropilenskim sigurnosnim zatvaračem za djecu i silika gelom kao sredstvom za sušenje koje sadržavaju 30 ili 100 tableta.
What Clopidogrel Teva Pharma B.V. contains 
Što Klopidogrel Teva Pharma B.V. sadrži
Tabulated list of adverse reactions 
Tabelični popis nuspojava
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous or exfoliative, urticaria, eczema, lichen planus 
bulozni dermatitis (toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme), angioedem, sindrom preosjetljivosti izazvane lijekom, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
Clopidogrel Teva Pharma B.V contains clopidogrel and belongs to a group of medicines called “platelet aggregation inhibitors.” It works by stopping certain particles in your blood (“platelets”) from sticking together to form blood clots which can block blood flow to important parts of your body including your heart and your brain. 
Lijek djeluje sprječavajući nakupljanje određenih čestica u krvi („trombocita“) i time stvaranje krvnih ugrušaka koji mogu blokirati dotok krvi do važnih organa, pa tako i mozga i srca.
Clopidogrel Teva Pharma B.V. contains hydrogenated castor oil. 
Klopidogrel Teva Pharma B.V. hidrogenirano ricinusovo ulje
Please note that instructions on how to remove the tablet from the blister strip are given on the outer carton of the peelable blisters. 
• Upute o vađenju tableta iz blistera nalaze se na kutiji u kojoj su blisteri s odvojivom folijom.
Other medicines and Clopidogrel Teva Pharma B.V. 
Drugi lijekovi i Klopidogrel Teva Pharma B.V
INFORMATION IN BRAILLE Clopidogrel Teva Pharma B.V. 75 mg 
PODACI NA BRAILLEOVOM PISMU Klopidogrel Teva Pharma B.V. 75 mg
Then, the usual dose is one 75-mg tablet of Clopidogrel Teva Pharma B.V. per day 
Nakon toga uobičajena doza lijeka Klopidogrel Teva Pharma B.V. je jedna tableta od 75 mg na dan.
See leaflet for further information 
Vidjeti Uputu o lijeku za dodatne informacije.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide). 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku klopidogrelbromida).
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA) - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. 
• odraslih bolesnika koji boluju od akutnog koronarnog sindroma: - Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom (ASK).
If you forget to take Clopidogrel Teva Pharma B.V. 
Ako ste zaboravili uzeti Klopidogrel Teva Pharma B.V.
Glomerulonephritis, blood creatinine increased 
Poremećaji bubrega i mokraćnog sustava glomerulonefritis, povećanje kreatinina u krvi
Very rare side effects (may affect up to 1 in 10,000 people): 
Vrlo rijetke nuspojave (may affect up to 1 in 10,000 people):
Prolonged bleeding, bleeding inside the head, bleeding in the eye, blood in the urine and/or purpura (red spots on the skin caused by bleeding underneath the skin) Rashes, itching, abnormal touch sensation 
• dulje krvarenje, krvarenje u glavi, krvarenje u oku, krv u urinu i/ili purpura (crvene mrlje na koži uzrokovane krvarenjem ispod površine kože)
Taste disturbances 
• poremećaj okusa
Severe reduction in certain blood cells leading to increased risk of bleeding or bruising, increased risk of infections, pale skin and extreme tiredness 
• izrazit pad broja crvenih krvnih stanica koji povećava rizik od krvarenja ili stvaranja modrica kao i rizik od infekcija te uzrokuje bljedilo i jaki umor
Discard 30 days after first opening 100 tablets HDPE bottle: Discard 100 days after first opening 
Bočica od polietilena visoke gustoće sa 100 tableta: Baciti 100 dana nakon prvog otvaranja bočice
30 tablets HDPE bottles: 
Bočice od polietilena visoke gustoće s 30 tableta:
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5). 
Ne preporučuje se istodobna primjena klopidogrela i drugih oralnih antikoagulanasa, jer to može pojačati intenzitet krvarenja (vidjeti dio
Read the package leaflet before use. 
NAČIN PRIMJENE Prije uporabe pročitajte Uputu o lijeku.
Clopidogrel Teva Pharma B.V. contains lactose. 
Klopidogrel Teva Pharma B.V sadrži laktozu.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA
You should not breastfeed while taking this medicine. 
Ovaj se lijek ne bi trebao primjenjivati tijekom dojenja.
Headache and dizziness 
• glavobolja i omaglica
Pregnancy and breast-feeding It is preferable not to use this medicine during pregnancy. 
Ne preporučuje se uzimanje ovog lijeka za vrijeme trudnoće.
Do not take Clopidogrel Teva Pharma B.V. 
Nemojte uzimati Klopidogrel Teva Pharma B.V.:
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR=23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR=7.3%; CI: -5.7 to 18.7 [p=0.258]). 
U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, PAD) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI:
Acute liver failure, hepatitis, abnormal liver function test 
Poremećaji jetre i žuči akutno zatajenje jetre, hepatitis, poremećaj jetrene funkcije
100 tablets HDPE bottles: 
Bočice od polietilena visoke gustoće sa 100 tableta:
+ ASA treatment group compared to the placebo + ASA group (1.4% versus 0.8%, respectively). 
U skupini klopidogrel + ASK zabilježen je veći broj intrakranijalnih krvarenja u odnosu na skupinu placebo + ASK (1,4% naspram 0,8%).
NAME OF THE MARKETING AUTHORISATION HOLDER Teva Pharma B.V. 
ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Teva Pharma B.V.
• Glycoprotein IIb/IIIa inhibitors (medicines used to stop blood clotting). 
• inhibitore glikoproteina IIb/IIIa (lijekove za zaustavljanje zgrušavanja krvi), primjerice abciksimab, eptifibatid ili tirofiban
• Ticlopidine, other antiplatelet agent. 
• tiklopidin ili druge antitrombocitne lijekove
GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to medical prescription 
NAČIN IZDAVANJA LIJEKA Lijek se izdaje na recept
Their use with Clopidogrel Teva Pharma B.V. is not recommended. 
Ne preporuča se njihova primjena s lijekom Klopidogrel Teva Pharma B.V.
Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel 
Klopidogrel Teva Pharma B.V. 75 mg filmom obložene tablete klopidogrel
Each film-coated tablet contains 75 mg of clopidogrel (as hydrobromide). 
Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku klopidogrelbromida).
How to take Clopidogrel Teva Pharma B.V. 
Kako uzimati Klopidogrel Teva Pharma B.V.
• Swelling in the mouth or skin disorders such as rashes, itching and blistering of the skin. 
• oticanje u ustima ili kožne poremećaje kao što su osip i svrbež te mjehurići na koži; ovi simptomi mogu biti znakovi alergijske reakcije.
Vascular disorders 
Pretrage trombocita
Film-coating 
NAČIN IZDAVANJALIJEKA
Inflammation of the blood vessels, decrease in blood pressure Yellowing of the skin and whites of the eyes (jaundice) Bleeding in the lungs, throat, stomach or bowels, abdomen or joints Bleeding of post-operative wounds or other serious bleeds Severe abdominal pain with or without back pain, pain in the joints and muscular pain Diarrhoea 
Poremećaji probavnog sustava gastrointestinalno krvarenje, proljev, bol u trbuhu, dispepsija ulkus želuca i dvanaesnika, gastritis, povraćanje, mučnina, konstipacija, flatulencija retroperitonealno krvarenje gastrointestinalno i retroperitonealno krvarenje s fatalnim ishodom, pankreatitis, kolitis (uključujući ulcerozni ili limfocitni kolitis), stomatitis
In CLARITY, there was an overall increase in bleeding in the clopidogrel plus ASA group vs. the placebo plus ASA group. 
U studiji CLARITY, uočeno je ukupno povećanje krvarenja u grupi koja je primala klopidogrel uz ASK u odnosu na skupinu koja je uzimala placebo uz ASK.
There was an excess of intracranial bleeding in the clopidogrel 
• krvarenje u trbušnoj šupljini
Push the tablet out 
Istisnuti tabletu.
How to store Clopidogrel Teva Pharma B.V. 
Kako čuvati Klopidogrel Teva Pharma B.V.
NAME OF THE MEDICINAL PRODUCT Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets 
NAZIV LIJEKA Klopidogrel Teva Pharma B.V 75 mg filmom obložene tablete
Warnings and precautions Tell your doctor before you start to take this medicine if: 
Prije nego što počnete uzimati ovaj lijek, obavijestite svojega liječnika:
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Clopidogrel Teva Pharma B.V. 75 mg film-coated tablets clopidogrel oral use 
NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Klopidogrel Teva Pharma B.V. 75 mg filmom obložene tablete klopidogrel
- Perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet. 
- Blisteri djeljivi na jedinične doze koji sadržavaju 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 filmom obloženih tableta.
Ulcers in the stomach and small intestine, nausea, vomiting, constipation, flatulence (wind) and inflammation of the stomach leading to sickness, loss of appetite and discomfort after eating Reduction in blood platelets which makes bleeding or bruising more likely Blood disorders including a reduction in the number of white blood cells which makes infections more likely. 
• Ulkus želuca i tankog crijeva, povraćanje, mučnina, zatvor, nadutost (vjetrovi) i upala želuca koja uzrokuje mučninu, gubitak apetita i neugodu nakon jela
The recommended dose is one 75 mg tablet per day which should be swallowed with water or another liquid. 
Preporučena doza je jedna tableta od 75 mg jednom na dan.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON of blisters (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet) 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKO PAKIRANJE blistera (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 filmom obloženih tableta)
• Diarrhoea, abdominal pain, indigestion or heartburn 
• proljev, bol u trbuhu, loša probava ili žgaravica.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Klopidogrel Teva Pharma B.V. sadrži laktozu Ako Vam je liječnik rekao da ne podnosite neke šećere, obratite mu se prije uzimanja ovog lijeka.
- Peelable perforated blisters contain 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablet. 
- Blisteri s odvojivom folijom djeljivi na jedinične doze koji sadržavaju 14x1, 28x1, 30x1, 50x1, 84x1, 90x1 ili 100x1 filmom obloženih tableta.
• Non-steroidal anti-inflammatory medicines (used to treat painful inflammatory conditions of the joints or muscles). 
• nesteroidne protuupalne lijekove, koji se obično primjenjuju za liječenje bolnih i/ili upalnih stanja mišića ili zglobova, primjerice ibuprofen, diklofenak i meloksikam,
Teva Pharma - Produtos Farmacêuticos Lda Tel: (351) 21 476 75 50 
Tel: (351) 21 476 75 50
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER (14x1, 28x1, 30x1, 50x1, 84x1, 90x1 or 100x1 film-coated tablets) 
PODACI KOJE NAJMANJE MORA SADRŽAVATI BLISTER ILI STRIP (BLISTER 14 x1, 28 x1,30x1, 50x1, 84 x1, 90x1 ili 100x1 filmom obloženih tableta)
Slovenská republika Teva Pharmaceuticals Slovakia s.r.o. 
Portugal Teva Pharma - Produtos Farmacêuticos Lda
1 of 1 
500 IU
Further information on RoActemra can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/RoActemra. 
Više informacija o lijeku RoActemra nalazi se na internetskim stranicama Agencije:ema.europa.eu/medicines/human/EPAR/RoActemra.
Patients were allowed to continue treatment with methotrexate during the study. 
Bolesnicima je bilo dopušteno nastaviti liječenje metotreksatom tijekom ispitivanja.
Cytokine release syndrome (CRS) 
Sindrom oslobađanja citokina (CRS)
All patients were also treated with a corticosteroid, which was stopped after reducing the dose gradually over 6 or 12 months. 
Svi bolesnici također su liječeni kortikosteroidom, no to je liječenje prekinuto nakon postupnog smanjenja doze u razdoblju od 6 ili 12 mjeseci.